Karydas Daphne 4

What Happened

• Daphne Karydas, a director of Mineralys Therapeutics (MLYS), received equity awards on Feb 19, 2026: 6,200 shares (RSUs) and 8,300 derivative awards, both acquired at $0.00 (grant).
• The RSUs are contingent rights to receive one share per RSU when they vest; the derivative award is a stock option-style grant. These are grants/compensation, not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-19; Form 4 filed: 2026-02-20 (timely).
• Grants: 6,200 RSUs @ $0.00 (acquired); 8,300 derivative awards @ $0.00 (acquired).
• Footnote F1: RSUs vest in one annual installment following the grant date (each RSU converts to one share upon vesting).
• Footnote F2: The stock option (derivative award) vests in 12 substantially equal monthly installments after the grant.
• Shares owned after the transaction: not provided in the excerpt supplied.
• No 10b5-1 plan, tax withholding sale, or late filing indicated in the provided data.

Context

• RSUs become actual shares only upon vesting, and the derivative award described vests over a year — neither represent immediate sellable stock at grant.
• Grants like these are routine compensation for directors; they do not by themselves indicate a buy or sell market signal.